Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
867 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Bronchogenic"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
3 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
4 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
Intervention:
5 Recruiting High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs
Conditions: Self Efficacy;   Drug Toxicity
Intervention: Drug: Erlotinib or Gefitinib
6 Recruiting Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Device: Endocutter
7 Recruiting TF2- Small Cell Lung Cancer Radio Immunotherapy
Conditions: Small Cell Lung Cancer;   CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
Interventions: Drug: Antibody TF2;   Radiation: IMP-288-Lutetium;   Radiation: IMP-288-Indium
8 Recruiting Hippocampus Avoidance PCI vs PCI
Conditions: Small Cell Lung Cancer;   Lung Cancer
Interventions: Radiation: Radiation Prophylactic Cranial Irradiation;   Radiation: Radiation Hippocampal Avoidance PCI
9 Recruiting Metformin in Stage IV Lung Adenocarcinoma
Condition: Non-small Cell Lung Cancer
Intervention: Drug: METFORMIN
10 Recruiting Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Paclitaxel  + Cisplatin;   Biological: CIK cell therapy
11 Recruiting Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
Condition: Non-small Cell Lung Cancer Stage III
Interventions: Drug: Erlotinib;   Drug: cis-platinum;   Drug: Vinorelbine
12 Recruiting Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Biological: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides
13 Recruiting 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
14 Not yet recruiting Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MEDI4736;   Drug: Placebo
15 Recruiting Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
Condition: Non Small Cell Lung Cancer
Intervention: Drug: erlotinib
16 Recruiting AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: AMG 102 and erlotinib
17 Recruiting Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Dietary Supplement: Ketogenic diet
18 Recruiting Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment
Condition: Small Cell Lung Cancer
Intervention: Genetic: Standard of care based on target(s) identified via GWS.
19 Recruiting The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Behavioral: Light Physical Activity;   Other: Symptom Experience Report
20 Recruiting CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years